DEF: Erasca, Inc. Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Erasca, Inc. announces its annual stockholders meeting to be held virtually on June 24, 2025, featuring proposals for director elections and ratification of the independent accounting firm.

Summary

• Erasca, Inc. will hold its Annual Meeting of Stockholders virtually on June 24, 2025, at 11:30 a.m. Pacific Time.
• Stockholders of record as of April 28, 2025, are entitled to vote at the meeting.
• The meeting will address the election of three Class I directors for a three-year term expiring in 2028.
• The meeting will also address the ratification of the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board recommends voting FOR the election of the director nominees and FOR the ratification of KPMG LLP's appointment.
• The proxy statement and the company's 2024 Annual Report are available online at www.proxydocs.com/ERAS.
• Stockholders can vote online, by phone, or by mail, following the instructions provided in the proxy materials.
• The company had 283,287,382 shares of common stock outstanding and entitled to vote as of the record date.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The information is presented clearly and professionally, indicating a well-managed company following standard procedures.

Positives

• The company is taking advantage of SEC rules to furnish proxy materials online, reducing costs and environmental impact.
• The Audit Committee is actively overseeing the company's financial reporting processes and the audits of its financial statements.
• The company has a compensation recovery (clawback) policy in place.
• The company has a written Code of Business Conduct and Ethics that applies to all employees, officers and directors.
• The company is pursuing environmental, social, and governance (ESG) initiatives that are aligned with its core mission.

Risks

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or control of the company.
• Directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds of the voting power of the then-outstanding shares of capital stock entitled to vote in the election of directors.

Future Outlook

The Board is not aware of any matter to be presented for action at the Annual Meeting other than the matters referred to above and does not intend to bring any other matters before the Annual Meeting. However, if other matters should come before the Annual Meeting, it is intended that holders of the proxies named on the Company's proxy card will vote thereon in their discretion.

Management Comments

• Jonathan E. Lim, M.D., Chairman, Chief Executive Officer, and Co-Founder, urges stockholders to promptly vote and submit their proxy.

Industry Context

This is a standard proxy statement for a publicly traded company, outlining the proposals to be voted on at the annual meeting and providing information to stockholders to make informed decisions.

Comparison to Industry Standards

• The structure and content of this proxy statement are consistent with industry standards for publicly traded companies in the United States.
• The director compensation program aligns with typical practices for companies of similar size and stage in the biotechnology industry.
• The company's corporate governance practices, including the establishment of independent committees and a code of ethics, are in line with Nasdaq listing requirements and best practices.

Related Party Transactions

• The company entered into an amended and restated stockholders agreement in April 2020 with the holders of its convertible preferred stock, including entities with which certain of its directors are affiliated.
• In May 2021, the company established the Erasca Foundation and issued 1,093,557 shares of its common stock to the Erasca Foundation as a contribution.
• In April 2023, the company loaned the Erasca Foundation $125,000 in exchange for a non-interest bearing promissory note that matured one year following the date of the note; the Erasca Foundation repaid this note in full in December 2023.
• In April 2024, the company made a donation of $125,000 to the Erasca Foundation.
• The company has entered into indemnification agreements with each of its directors and executive officers.

Stakeholder Impact

• Shareholders are provided with the opportunity to vote on key decisions regarding the company's governance and direction.
• Employees are subject to the company's Code of Business Conduct and Ethics and insider trading compliance policy.
• The Erasca Foundation supports various initiatives that positively impact society, including providing funding to organizations focused on cancer research and patient support.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and report the final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, KPMG, Stockholders, Corporate Governance, Executive Compensation, Erasca